Blog
RSS FeedPosted by Michael Wonder on 09 Sep 2021
Consumers to have more say on medicine access issues
7 September 2021 - Consumer involvement in Australia’s medicines choices has been further strengthened under a new strategic agreement Medicines ...
Posted by Michael Wonder on 25 Jul 2021
Patient advocacy organisations and FDA drug approval: lessons from Aduhelm
23 July 2021 - In the wake of last month’s controversial FDA approval of Biogen’s Aduhelm, Alzheimer’s Association CEO Harry ...
Posted by Michael Wonder on 14 Jul 2021
NICE feedback?
13 July 2021 - NICE is quite far along a NICE led process to review its methods and processes for ...
Posted by Michael Wonder on 12 Jul 2021
CMS opens national coverage determination analysis on treatment for Alzheimer’s disease
12 July 2021 - Today, the Centers for Medicare & Medicaid Services is opening a National Coverage Determination analysis, a ...
Posted by Michael Wonder on 01 Jul 2021
PHARMAC is seeking views on declining funding applications
29 June 2021 - PHARMAC is considering declining 97 inactive medicine funding applications. ...
Posted by Michael Wonder on 24 Jun 2021
Moving patient stories highlight opportunities to strengthen our health care systems for all Australians
24 June 2021 - It was an emotional evening among the nearly 200 in-person and online attendees at Parliament House last ...
Posted by Michael Wonder on 18 Jun 2021
Efficient funding of chemotherapy review - submissions on discussion paper
18 June 2021 - The efficient funding of chemotherapy review discussion paper was released on 21 May 2021 to gain ...
Posted by Michael Wonder on 16 Jun 2021
MSAC consultation process - changes to take effect from 1 July 2021
16 June 2021 - MSAC is implementing changes to its consultation process from 1 July 2021. ...
Posted by Michael Wonder on 04 Feb 2021
Repurposing of prescription medicines
4 February 2021 - The Therapeutic Goods Administration is conducting a public consultation that seeks to understand potential obstacles and ...
Posted by Michael Wonder on 20 Jan 2021
The representation of public values in health technology assessment to inform funding decisions: the case of Australia's national funding bodies
18 January 2021 - Historically, Australia has been at the forefront of the application of HTA for assessing the effectiveness and ...
Posted by Michael Wonder on 16 Jan 2021
Strengthening patient outcome evidence in health technology assessment: a coproduction approach
13 January 2021 - NICE worked with patients and staff from six patient organisations to review existing health technology assessment ...
Posted by Michael Wonder on 13 Oct 2020
Stage 2 PBS process improvements – consultation closed
13 October 2020 - On 21 September 2020, the department hosted a webinar to provide information to industry on the ...
Posted by Michael Wonder on 02 Oct 2020
Patients, users, caregivers, and citizens' involvement in local health technology assessment unit in Quebec: a survey
29 September 2020 - The aim of the survey was to provide an overview of local health technology assessment unit practices ...
Posted by Michael Wonder on 10 Sep 2020
PHARMAC seeking views on widened access to juvenile idiopathic arthritis medicines
11 September 2020 - PHARMAC is looking at widening access to three funded treatments – adalimumab, etanercept and tocilizumab – to ...
Posted by Michael Wonder on 09 Sep 2020
PHARMAC seeking views on new type 2 diabetes medicines
9 September 2020 - PHARMAC is looking at funding two new medicines with substantial health benefits for up to 50,000 ...